Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
17.03
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-6.03 Insider Own9.41% Shs Outstand48.99M Perf Week-9.66%
Market Cap834.30M Forward P/E- EPS next Y-2.06 Insider Trans-3.46% Shs Float44.38M Perf Month-23.73%
Income-263.49M PEG- EPS next Q-1.26 Inst Own79.16% Short Float8.89% Perf Quarter20.27%
Sales90.24M P/S9.25 EPS this Y31.73% Inst Trans-3.02% Short Ratio5.37 Perf Half Y4.80%
Book/sh7.08 P/B2.41 EPS next Y49.94% ROA-37.45% Short Interest3.95M Perf Year-11.99%
Cash/sh5.62 P/C3.03 EPS next 5Y13.60% ROE-63.65% 52W Range11.83 - 28.80 Perf YTD-5.13%
Dividend Est.- P/FCF- EPS past 5Y- ROI-66.88% 52W High-40.87% Beta1.35
Dividend TTM- Quick Ratio2.57 Sales past 5Y72.63% Gross Margin39.57% 52W Low43.96% ATR (14)1.21
Dividend Ex-Date- Current Ratio2.57 EPS Y/Y TTM7.24% Oper. Margin-297.12% RSI (14)29.79 Volatility5.66% 5.37%
Employees344 Debt/Eq0.29 Sales Y/Y TTM-19.94% Profit Margin-291.99% Recom1.42 Target Price39.83
Option/ShortYes / Yes LT Debt/Eq0.26 EPS Q/Q-3.25% Payout- Rel Volume0.00 Prev Close17.03
Sales Surprise-34.69% EPS Surprise-12.57% Sales Q/Q-29.13% EarningsFeb 27 AMC Avg Volume734.70K Price17.03
SMA20-14.94% SMA50-13.94% SMA200-4.96% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-11-24Initiated H.C. Wainwright Buy $36
Mar-08-24Upgrade RBC Capital Mkts Sector Perform → Outperform $20 → $35
Mar-06-24Upgrade Leerink Partners Market Perform → Outperform $37
Feb-21-24Resumed Raymond James Outperform $45
Nov-01-23Initiated Stifel Buy $35
Jun-02-23Initiated Robert W. Baird Outperform $42
Jun-23-22Initiated Berenberg Buy $61
Dec-15-21Initiated Wedbush Neutral $29
Oct-19-21Resumed Morgan Stanley Overweight $62 → $50
Jan-06-21Upgrade Raymond James Outperform → Strong Buy $60
Mar-28-24 01:09PM
07:05AM
Mar-27-24 04:05PM
Mar-18-24 07:00PM
Mar-13-24 08:00AM
07:05AM Loading…
Mar-11-24 07:05AM
Mar-08-24 01:29AM
Mar-06-24 11:20PM
04:10PM
11:33AM
03:01AM
Mar-05-24 07:05AM
Feb-29-24 04:57PM
Feb-28-24 11:05AM
09:36AM
05:35PM Loading…
Feb-27-24 05:35PM
04:41PM
04:32PM
04:05PM
Feb-21-24 07:05AM
Feb-17-24 12:07AM
Feb-08-24 09:36AM
04:50AM
Feb-07-24 11:40AM
07:05AM
Jan-31-24 07:05AM
Jan-18-24 09:01PM
Jan-16-24 02:47PM
Jan-10-24 07:05AM
Jan-09-24 06:20PM
07:05AM Loading…
Jan-08-24 07:05AM
Dec-22-23 09:01AM
Nov-29-23 07:05AM
Nov-16-23 09:55AM
Nov-09-23 04:46PM
06:37AM
Nov-08-23 04:42PM
04:05PM
Nov-07-23 07:05AM
Nov-03-23 06:53PM
Nov-01-23 07:05AM
Oct-30-23 07:05AM
Oct-05-23 07:05AM
Oct-03-23 04:05PM
Sep-26-23 07:05AM
Sep-05-23 07:05AM
Aug-30-23 07:05AM
Aug-23-23 04:05PM
Aug-02-23 05:55PM
04:41PM
04:05PM
Aug-01-23 04:05PM
Jul-26-23 07:05AM
Jul-24-23 04:05PM
Jul-11-23 07:05AM
Jul-01-23 10:09AM
Jun-27-23 07:05AM
Jun-21-23 08:00PM
Jun-20-23 08:00AM
Jun-04-23 09:15AM
Jun-01-23 07:05AM
May-23-23 07:05AM
May-22-23 07:05AM
May-16-23 05:52PM
May-08-23 07:05AM
06:02AM
May-04-23 06:44AM
May-03-23 05:55PM
04:47PM
04:05PM
May-02-23 04:53PM
Apr-26-23 08:00PM
04:05PM
Apr-18-23 07:05AM
Apr-15-23 08:20AM
08:12AM
Apr-11-23 07:05AM
Mar-08-23 07:05AM
Mar-05-23 07:19AM
Mar-02-23 05:51AM
Feb-28-23 08:25PM
04:05PM
Feb-24-23 09:20AM
Feb-22-23 03:00PM
10:00AM
Feb-21-23 07:05AM
Feb-17-23 07:05AM
Feb-11-23 08:40AM
Feb-08-23 07:05AM
Feb-06-23 07:05AM
Jan-26-23 08:00AM
Jan-23-23 11:46AM
07:05AM
Jan-10-23 01:58PM
Jan-09-23 04:01PM
Jan-03-23 07:05AM
Dec-21-22 07:05AM
Dec-08-22 07:05AM
Dec-03-22 08:26AM
Nov-30-22 02:36PM
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mills Kenneth T.President and CEOApr 15 '24Option Exercise3.7615,00056,400423,035Apr 17 05:05 PM
Mills Kenneth T.President and CEOApr 15 '24Sale18.1915,000272,871408,035Apr 17 05:05 PM
Vasista VittalChief Financial OfficerMar 19 '24Option Exercise3.7620,04175,354246,534Mar 21 05:20 PM
Mills Kenneth T.President and CEOMar 14 '24Option Exercise3.7615,00056,400423,035Mar 18 05:03 PM
Mills Kenneth T.President and CEOMar 14 '24Sale21.8615,000327,942408,035Mar 18 05:03 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Option Exercise22.2512,878286,536120,070Mar 07 06:05 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Sale28.3612,878365,220107,192Mar 07 06:05 PM
Mills Kenneth T.President and CEOFeb 14 '24Option Exercise3.7615,00056,400423,035Feb 16 06:28 PM
Mills Kenneth T.President and CEOFeb 14 '24Sale16.7615,000251,349408,035Feb 16 06:28 PM
Mills Kenneth T.President and CEOJan 16 '24Option Exercise3.7645,000169,200453,035Jan 18 06:39 PM
Mills Kenneth T.President and CEOJan 16 '24Sale15.1845,000682,992408,035Jan 18 06:39 PM
PAKOLA STEVEChief Medical OfficerJan 03 '24Sale17.3917,237299,789107,192Jan 04 04:23 PM
Mills Kenneth T.President and CEODec 19 '23Option Exercise3.6645,000164,835400,289Dec 21 01:38 PM
Mills Kenneth T.President and CEODec 19 '23Sale19.6845,000885,825355,289Dec 21 01:38 PM
Vasista VittalChief Financial OfficerMay 31 '23Option Exercise0.8535,00029,750215,001Jun 02 04:12 PM